Our study is the first to demonstrate the critical role of SPP1 signaling in post‐ICH depression through modulation of the Nrf2/BDNF pathway, providing novel therapeutic targets for clinical management of this debilitating neuropsychiatric sequela. Here, BDNF is linked to major depressive disorder.